Jesus Gonzalez Lugo, M.D.

Professional Background

Dr. Gonzalez Lugo completed his Internal Medicine Residency at Albert Einstein College of Medicine. He proceeded to complete his Hematology and Oncology Fellowship at Montefiore Medical Center, Albert Einstein College of Medicine, where he also served as chief fellow. He is the principal investigator for multiple ongoing studies focused on higher-risk MDS and Acute Myeloid Leukemias. He is the recipient of numerous awards including the ASH Abstract Achievement Award, SOHO Young Investigator Award, the European Hematology Association Young Investigator Travel Grant, and most recently the Robert A. Winn Excellence in Clinical Trials Career Development Award.

His clinical and research interests include Myelodysplastic Syndromes, CMML, VEXAS Syndrome and Acute Leukemias.

• MD, Doctor of Medicine, Universidad de Monterrey, Monterrey, Mexico
• Residency, Internal Medicine, Jacobi Medical Center/ Albert Einstein College of Medicine, Bronx, New York
• Clinical Fellowship, Hematology and Medical Oncology, Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, New York

• American Society of Clinical Oncology, Member, 2018 - Present
• American Society of Hematology, Member, 2018 - Present

---

• Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, Verma A, Halmos B. 2021. Seroconversion rates following COVID-19 vaccination among patients with cancer.. Cancer cell, 39 (8), 1081-1090.e2
• Billett HH, Reyes-Gil M, Szymanski J, Ikemura K, Stahl LR, Lo Y, Rahman S, Gonzalez-Lugo JD, Kushnir M, Barouqa M, Golestaneh L, Bellin E. 2020. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.. Thrombosis and haemostasis, 120 (12), 1691-1699
• Shastri A, Gonzalez-Lugo J, Verma A. 2020. Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies.. Blood cancer discovery, 2 (2), 113-115
• Gonzalez-Lugo JD, Chakraborty S, Verma A, Shastri A. 2021. The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.. Seminars in hematology, 58 (1), 56-65
• Gonzalez-Lugo JD, Kambhampati S, Yacoub A, Donnellan WB, Berdeja J, Bhagat P, Fehn K, Remy C, Jasra S, Kazemi M, Pradhan K, Kim M, Mantzaris I, Sica RA, Shah N, Goldfinger M, Kornblum N, Gritsman K, Braunschweig I, Steidl U, Will B, Shastri A, Verma A. 2022. Lenalidomide and Eltrombopag for Treatment of Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Clinical Trial.. Clinical Cancer Research